Rimonabant, a cannabinoid CB1 receptor antagonist, attenuates mechanical allodynia and counteracts oxidative stress and nerve growth factor deficit in diabetic mice

European Journal of Pharmacology

Volumn 637, Issue 1-3, 2010, Pages 62-69

  Comelli, Francesca ^a   Bettoni, Isabella ^a   Colombo, Anita ^a   Fumagalli, Pietro ^a   Giagnoni, Gabriella ^a   Costa, Barbara ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Cannabinoid; Diabetes; Nerve growth factor; Neuropathy; Pain; Rimonabant

Indexed keywords

CAPSAZEPINE; GLUCOSE; GLUTATHIONE; NERVE GROWTH FACTOR; RIMONABANT; TUMOR NECROSIS FACTOR ALPHA; CANNABINOID 1 RECEPTOR; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEMYELINATION; DIABETIC NEUROPATHY; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; MALE; MOUSE; NERVE DEGENERATION; NERVE REGENERATION; NEUROPATHIC PAIN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RETREATMENT; STREPTOZOCIN DIABETES; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT REDUCTION; ANIMAL; C57BL MOUSE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; HINDLIMB; METABOLISM; PAIN; PAIN ASSESSMENT; PATHOLOGY; SCIATIC NERVE; STIMULATION; TIME;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; HINDLIMB; MALE; MICE; MICE, INBRED C57BL; NERVE GROWTH FACTORS; OXIDATIVE STRESS; PAIN; PAIN MEASUREMENT; PHYSICAL STIMULATION; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; SCIATIC NERVE; TIME FACTORS;

EID: 77953285673     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.03.061     Document Type: Article

References (40)

1. Ahluwalia J., Urban L., Capogna M., Bevan S., Nagy I. Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons. Neuroscience 2000, 100:685-688.
2. Apfel S.C., Schwartz S., Adornato B.T., Freeman R., Biton V., Rendell M., Vinik A., Giuliani M., Stevens J.C., Barbano R., Dyck P.J. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial. rhNGF Clinical Investigator Group. JAMA 2000, 284:2215-2221.
3. Balakumar P., Arora M.K., Ganti S.S., Reddy J., Singh M. Recent advances in pharmacotherapy for diabetic nephropathy: current perspectives and future directions. Pharmacol. Res. 2009, 60:24-32.
4. Baron R. Peripheral neuropathic pain: from mechanisms to symptoms. Clin. J. Pain 2000, 16:S12-S20.
5. Bravenboer B., Kappelle A.C., Hamers F.P., van Buren T., Erkelens D.W., Gispen W.H. Potential use of glutathione for the prevention and treatment of diabetic neuropathy in the streptozotocin-induced diabetic rat. Diabetologia 1992, 35:813-814.
6. Caterina M.J., Julius D. The vanilloid receptor: a molecular gateway to the pain pathway. Ann. Rev. Neurosci. 2001, 24:487-517.
7. 1 receptor antagonist, SR141716A, selectively facilitates nociceptive responses of dorsal neurones in the rat. Br. J. Pharmacol. 1999, 127:1765-1767.
8. Colleoni, M., Sacerdote, P., in press. Murine models of human neuropathic pain. Biochim. Biophys. Acta. http://doi:10.1016/j.bbadis.2009.10.012.
9. Costa B., Trovato A.E., Colleoni M., Giagnoni G., Zarini E., Croci T. Effect of the cannabinoid CB1 receptor antagonist, SR141716, on nociceptive response and nerve demyelination in rodents with chronic constriction injury of the sciatic nerve. Pain 2005, 116:52-61.
10. Courteix C., Eschalier A., Lavarenne J. Streptozocin-induced diabetic rats: behavioural evidence for a model of chronic pain. Pain 1993, 53:81-88.
11. Feldman E.L., Russell J.W., Sullivan K.A., Golovoy D. New insights into the pathogenesis of diabetic neuropathy. Curr. Opin. Neurol. 1999, 12:553-563.
12. Fioravanti B., De Felice M., Stucky C.L., Medler K.A., Luo M.C., Gardell L.R., Ibrahim M., Malan T.P., Yamamura H.I., Ossipov M.H., King T., Lai J., Porreca F., Vanderah T.W. Constitutive activity at the cannabinoid CB1 receptor is required for behavioral response to noxious chemical stimulation of TRPV1: antinociceptive actions of CB1 inverse agonists. J. Neurosci. 2008, 28:11593-11602.
13. Garrett N.E., Malcangio M., Dewhurst M., Tomlinson D.R. Alpha-lipoic acid corrects neuropeptide deficits in diabetic rats via induction of trophic support. Neurosci. Lett. 1997, 222:191-194.
14. Gavva N.R., Treanor J.J., Garami A., Fang L., Surapaneni S., Akrami A., Alvarez F., Bak A., Darling M., Gore A., Jang G.R., Kesslak J.P., Ni L., Norman M.H., Palluconi G., Rose M.J., Salfi M., Tan E., Romanovsky A.A., Banfield C., Davar G. Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans. Pain 2008, 136:202-210.
15. Gordin D., Forsblom C., Rönnback M., Parkkonen M., Wadén J., Hietala K., Groop P.H. Acute hyperglycaemia induces an inflammatory response in young patients with type 1 diabetes. Ann. Med. 2008, 40:627-633.
16. Herzberg U., Eliav E., Bennett G.J., Kopin I.J. The analgesic effects of R(+)-WIN 55, 212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci. Lett. 1997, 221:157-160.
17. Hissin P.J., Hilf R. A fluorometric method for determination of oxidized and reduced glutathione in tissues. Anal. Biochem. 1976, 74:214-226.
18. Kalichman M.W., Powell H.C., Mizisin A.P. Reactive, degenerative, and proliferative Schwann cell responses in experimental galactose and human diabetic neuropathy. Acta Neuropathol. 1998, 95:47-56.
19. Lever I.J., Rice A.S. Cannabinoids and pain. Handb. Exp. Pharmacol. 2007, 177:265-306.
20. Martin C.L., Albers J., Herman W.H., Cleary P., Waberski B., Greene D.A., Stevens M.J., Feldman E.L. Neuropathy among the diabetes control and complications trial cohort 8years after trial completion. Diabetes Care 2006, 29:340-344.
21. Nogueiras R., Veyrat-Durebex C., Suchanek P.M., Klein M., Tschöp J., Caldwell C., Woods S.C., Wittmann G., Watanabe M., Liposits Z., Fekete C., Reizes O., Rohner-Jeanrenaud F., Tschöp M.H. Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats. Diabetes 2008, 57:2977-2991.
22. Obrosova I.G., Fathallah L., Stevens M.J. Taurine counteracts oxidative stress and nerve growth factor deficit in early experimental diabetic neuropathy. Exp. Neurol. 2001, 172:211-219.
23. Ohkawa H., Ohishi N., Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 1979, 95:351-358.
24. Pertwee R.G. The pharmacology of cannabinoid receptors and their ligands: an overview. Int. J. Obes. (Lond.) 2006, 30:S13-S18.
25. Pittenger G., Vinik A. Nerve growth factor and diabetic neuropathy. Exp. Diab. Res. 2003, 4:271-285.
26. Qiang X., Satoh J., Sagara M., Fukuzawa M., Masuda T., Sakata Y., Muto G., Muto Y., Takahashi K., Toyota T. Inhibitory effect of troglitazone on diabetic neuropathy in streptozotocin-induced diabetic rats. Diabetologia 1998, 41:1321-1326.
27. Rinaldi-Carmona M., Barth F., Heaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Ne'liat G., Caput D., Ferrara P., Soubrié P., Breliére J.C., Le Fur G. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 1994, 350:240-244.
28. Rosenstock J., Hollander P., Chevalier S., Iranmanesh A. SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes. Diabetes Care 2008, 31:2169-2176.
29. Sagara M., Satoh J., Wada R., Yagihashi S., Takahashi K., Fukuzawa M., Muto G., Muto Y., Toyota T. Inhibition of development of peripheral neuropathy in streptozotocin-induced diabetic rats with N-acetylcysteine. Diabetologia 1996, 39:263-269.
30. Scheen A.J., Finer N., Hollander P., Jensen M.D., Van Gaal L.F. Efficacy and tolerability of rimonabant in overweight or obese patients with type II diabetes: a randomized controlled study. Lancet 2006, 368:1660-1672.
31. Smart D., Gunthorpe M.J., Jerman J.C., Nasir S., Gray J., Muir A.I., Chambers J.K., Randall A.D., Davis J.B. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br. J. Pharmacol. 2000, 129:227-230.
32. Strangman N.M., Patrick S.L., Hohmann A.G., Tsou K., Walker J.M. Evidence for a role of endogenous cannabinoids in the modulation of acute and tonic pain sensitivity. Brain Res. 1998, 813:323-328.
33. Szallasi A., Cortright D.N., Blum C.A., Eid S.R. The vanilloid receptor TRPV1: 10years from channel cloning to antagonist proof-of-concept. Nat. Rev. Drug Discov. 2007, 6:357-372.
34. Tanaka S., Seino H., Satoh J., Fujii N., Rikiishi H., Zhu X.P., Takahashi K., Sagara M., Nobunaga T., Toyota T. Increased in vivo production of tumor necrosis factor after development of diabetes in nontreated, long-term diabetic BB rats. Clin. Immunol. Immunopathol. 1992, 62:258-263.
35. Van Gaal L., Pi-Sunyer X., Després J.P., McCarthy C., Scheen A. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care 2008, 31:S229-S240.
36. Vincent A.M., Russell J.W., Low P., Feldman E.L. Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr. Rev. 2004, 25:612-628.
37. Walker K.M., Urban L., Medhurst S.J., Patel S., Panesar M., Fox A.J., McIntyre P. The VR1 antagonist capsazepine reverses mechanical hyperalgesia in models of inflammatory and neuropathic pain. J. Pharmacol. Exp. Ther. 2003, 304:56-62.
38. Welch S.P., Huffman J.W., Lowe J. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A. J. Pharmacol. Exp. Ther. 1998, 286:1301-1308.
39. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983, 16:109-110.
40. Zygmunt P.M., Petersson J., Andersson D.A., Chuang H., Sørgård M., Di Marzo V., Julius D., Högestätt E.D. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999, 400:452-457.